Filing Details
- Accession Number:
- 0001179110-14-012736
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-08-12 13:51:23
- Reporting Period:
- 2014-08-08
- Filing Date:
- 2014-08-12
- Accepted Time:
- 2014-08-12 13:51:23
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1065087 | Albany Molecular Research Inc | AMRI | Services-Commercial Physical & Biological Research (8731) | 141742717 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1449207 | R Steven Hagen | 26 Corporate Circle Albany NY 12203 | Svp Pharmaceutical Dev & Mfg | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2014-08-08 | 797 | $18.99 | 30,933 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2014-08-08 | 10,000 | $5.25 | 40,933 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-08-08 | 10,000 | $18.99 | 30,933 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Option to Purchase Common Stock | Acquisiton | 2014-08-08 | 10,000 | $5.25 | 10,000 | $5.25 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
1,250 | 2021-06-02 | No | 4 | M | Direct |
Footnotes
- 100% of grant is time based. Time based grant vests 25% per year on each of the first 4 anniversaries of the date of grant (June 2, 2011). Performance based grant vests 25% per year on each of the first 4 anniversaries of the grant date if (1) certain performance criteria related to the Company's operating profitabilityare reached and (2) the grantee is employed on such anniversary date; if the foregoing criteria are not met on any anniversary date, 25% of the shares of options under theperformance award will immediately be forfeited. The 10,000 shares being exercised represent a portion of the vested grants. 25% of the initial grant is not yet exercisable.
- 2. The reported price represents the weighted average sales price for such shares. The actual range of sales prices for such shares was $18.89 - $19.14. Upon request of the Commission, the exact number of shares sold at each price will be provided.